阿斯利康在华面临800万美元新罚款？公司回应了

Core Viewpoint - AstraZeneca may face a new fine of $8 million in China related to unpaid taxes on the breast cancer drug Enhertu, in addition to a potential fine of up to $4.5 million for two other cancer drugs, Imfinzi and Imjudo [1][2]. Group 1: Financial Performance - Enhertu's sales for the fiscal year 2024 are projected to be ¥552.8 billion (approximately $3.654 billion), representing a year-on-year growth of 39.6%, with revenue from China at ¥10.3 billion (about $0.68 billion), up 57.1% year-on-year [1]. - For fiscal year 2025, Enhertu's revenue is expected to reach ¥662.1 billion (approximately $4.377 billion) [1]. - In the first quarter of this year, Enhertu's sales amounted to $1.086 billion [1]. Group 2: Regulatory Issues - AstraZeneca is under investigation for allegedly failing to pay import taxes, with the Shenzhen Customs issuing a notice indicating potential tax evasion of over $1.6 million related to Enhertu [2]. - The company has also received a notice from the Shenzhen Public Security Bureau regarding allegations of infringing on personal information, but claims no illegal gains from such actions [3]. - AstraZeneca has stated its commitment to cooperate fully with Chinese authorities regarding these investigations [3]. Group 3: Market Position - Enhertu has covered 90% of the metastatic breast cancer population and received approval for a sixth indication in the U.S. for specific types of breast cancer [2]. - The company has submitted a new indication application for Enhertu in China as of April this year [2].